iSpecimen Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
iSpecimen Inc. (ISPC) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $30.77 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $15.52K, a 6.26% increase year-over-year.
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $15.25K, a 6.12% increase year-over-year.
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $14.99K, a 6.06% increase year-over-year.
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $14.86K, a 52.44% decline year-over-year.
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $58.82K, a 53.69% decline from fiscal 2024.
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $127.01K, a 19.20% decline from fiscal 2023.
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $157.19K, a 5.90% increase from fiscal 2022.
- iSpecimen Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $148.43K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $30.77K 10-Q · filed 2026-08-14 | $45.76K derived: sum of 3 quarters · filed 2026-08-14 | $60.61K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $15.25K 10-Q · filed 2026-05-18 | $30.23K derived: sum of 2 quarters · filed 2026-05-18 | $45.09K derived: sum of 3 quarters · filed 2026-05-18 | $59.70K derived: sum of 4 quarters · filed 2026-05-18 |
| 2025-12-31 | $14.99K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $29.84K derived: sum of 2 quarters · filed 2026-04-01 | $44.45K derived: sum of 3 quarters · filed 2026-04-01 | $58.82K 10-K · filed 2026-04-01 |
| 2025-09-30 | $14.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $29.46K derived: sum of 2 quarters · filed 2025-11-17 | $43.83K 10-Q · filed 2025-11-17 | $57.96K derived: sum of 4 quarters · filed 2025-11-17 |
| 2025-06-30 | $14.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $28.98K 10-Q · filed 2025-08-14 | $43.11K derived: sum of 3 quarters · filed 2025-08-14 | $74.34K derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $14.37K 10-Q · filed 2025-05-19 | $28.50K derived: sum of 2 quarters · filed 2025-05-19 | $59.73K derived: sum of 3 quarters · filed 2025-05-19 | $100.86K derived: sum of 4 quarters · filed 2025-05-19 |
| 2024-12-31 | $14.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $45.37K derived: sum of 2 quarters · filed 2025-04-14 | $86.49K derived: sum of 3 quarters · filed 2025-04-14 | $127.01K 10-K · filed 2025-04-14 |
| 2024-09-30 | $31.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $72.36K derived: sum of 2 quarters · filed 2024-11-07 | $112.88K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $41.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $81.64K 10-Q · filed 2024-08-06 | ||
| 2024-03-31 | $40.52K 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $157.19K 10-K · filed 2024-03-13 | |||
| 2023-06-30 | $39.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $77.58K 10-Q · filed 2023-08-02 | $115.51K derived: sum of 3 quarters · filed 2023-08-02 | $152.89K derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | $38.50K 10-Q · filed 2023-05-04 | $76.43K derived: sum of 2 quarters · filed 2023-05-04 | $113.81K derived: sum of 3 quarters · filed 2023-05-04 | $150.64K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $37.93K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $75.31K derived: sum of 2 quarters · filed 2023-03-30 | $112.14K derived: sum of 3 quarters · filed 2023-03-30 | $148.43K 10-K/A · filed 2023-03-30 |
| 2022-09-30 | $37.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $74.21K derived: sum of 2 quarters · filed 2022-11-08 | $110.50K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $36.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $73.12K 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $36.29K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |